Selected article for: "preventive vaccine and vaccine development"
Author: Amawi, Haneen; Abu Deiab, Ghina'a I; A Aljabali, Alaa A; Dua, Kamal; Tambuwala, Murtaza M
Title: COVID-19 pandemic: an overview of epidemiology, parthenogenesis, diagnostics and potential vaccines and therapeutics
  • Cord-id: b0aaozmn
  • Document date: 2020_5_13
    • ID: b0aaozmn
    Snippet: At the time of writing this review, severe acute respiratory coronavirus syndrome-2 (SARS-CoV-2) has infected more than 2,355,853 patients and resulted in more than 164,656 deaths worldwide (as of 20 April 2020). This review highlights the preventive measures, available clinical therapies and the potential of vaccine development against SARS-CoV-2 by taking into consideration the strong genetic similarities of the 2003 epidemic SARS-CoV. Recent studies are investigating the repurposing of US FDA
    Document: At the time of writing this review, severe acute respiratory coronavirus syndrome-2 (SARS-CoV-2) has infected more than 2,355,853 patients and resulted in more than 164,656 deaths worldwide (as of 20 April 2020). This review highlights the preventive measures, available clinical therapies and the potential of vaccine development against SARS-CoV-2 by taking into consideration the strong genetic similarities of the 2003 epidemic SARS-CoV. Recent studies are investigating the repurposing of US FDA-approved drugs as there is no available vaccine yet with many attempts under clinical evaluation. Several antivirals, antimalarials and immunomodulators that have shown activity against SARS-CoV and Middle East coronavirus respiratory syndromes are being evaluated. In particular, hydroxychloroquine, remdesivir, favipiravir, arbidol, tocilizumab and bevacizumab have shown promising results. The main aim of this review is to provide an overview of this pandemic and where we currently stand.

    Search related documents:
    Co phrase search for related documents
    • abnormal vomiting and acute respiratory syndrome: 1, 2
    • abnormal vomiting and acute sars cov respiratory coronavirus syndrome: 1
    • abnormal vomiting and liver function: 1, 2, 3, 4, 5, 6
    • abnormal vomiting and liver function test: 1
    • abnormal vomiting and liver injury: 1
    • acceptable safety profile and acute kidney injury: 1
    • acceptable safety profile and acute respiratory coronavirus: 1, 2, 3, 4, 5, 6, 7, 8
    • acceptable safety profile and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8
    • acceptable safety profile and acute sars cov respiratory coronavirus syndrome: 1, 2, 3, 4, 5, 6
    • acceptable safety profile and additional benefit: 1
    • acceptable safety profile and lung infection: 1